Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Expert Opin Ther Pat. 2016;26(3):323–345. doi: 10.1517/13543776.2016.1154045

Figure 3.

Figure 3

A) Number of patents and patent applications reported by SciFinder®, Espacenet, and Google Patent Search over the period of 1990 – present having human FXIa as the main druggable target or one of the potential targets for the claimed technology. The search was performed using the key words “Factor XIa Inhibitors” and “FXIa Inhibitors” to uncover about 85 patents and patent applications. B) Number of patents of FXIa inhibitors relative to those filed for FXa and thrombin over the last decade, as reported by SciFinder® using the corresponding key words. Number of patents and patent applications for FXIa inhibitors was similar or exceeded those filed for thrombin or FXa inhibitors only starting 2010. C) Distribution of FXIa inhibition/inhibitors related publications (articles, reviews, letters, editorials, abstracts, chapters, proceedings, notes, but not patents) among different research areas starting 1990 as reported by Web of Science using the above key words. It is clearly indicated that the predominant research areas over the last 25 years are related to hematology and cardiovascular aspects in addition to biochemical and molecular biology aspects, and that reporting on medicinal chemistry and design efforts toward FXIa inhibitors started only a decade ago.